Industry: Healthcare
Published Date: June-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 219
Report ID: PMRREP34570
1. Executive Summary
1.1. Global Retinal Biologics Market Snapshot, 2024 and 2031
1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Value Chain Analysis
3.3. Key Deals and Mergers
3.4. PESTLE Analysis
3.5. Porter's Five Force Analysis
4. Global Retinal Biologics Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
4.1. Key Highlights
4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Mn) Analysis, 2018-2022
4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2023-2031
4.3. Global Retinal Biologics Market Outlook: Drug Class
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2018 - 2022
4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
4.3.3.1. VEGF-A Antagonists
4.3.3.2. TNF-a Inhibitors
4.4. Market Attractiveness Analysis: Drug Class
4.5. Global Retinal Biologics Market Outlook: Indication
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2018 - 2022
4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
4.5.3.1. Macular Degeneration
4.5.3.2. Diabetic Macular Edema
4.5.3.3. Diabetic Retinopathy
4.5.3.4. Uveitis
4.5.3.5. Others
4.6. Market Attractiveness Analysis: Indication
4.7. Global Retinal Biologics Market Outlook: Distribution Channel
4.7.1. Introduction / Key Findings
4.7.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2018 - 2022
4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2023 - 2031
4.7.3.1. Institutional Sales
4.7.3.2. Retail Pharmacies
4.7.3.3. Mail Order Pharmacies
4.7.3.4. Retail Sales
4.8. Market Attractiveness Analysis: Distribution Channel
5. Global Retinal Biologics Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2018 - 2022
5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2023 - 2031
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Retinal Biologics Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
6.2.1. By Country
6.2.2. By Drug Class
6.2.3. By Indication
6.2.4. By Distribution Channel
6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
6.4.1. VEGF-A Antagonists
6.4.2. TNF-a Inhibitors
6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
6.5.1. Macular Degeneration
6.5.2. Diabetic Macular Edema
6.5.3. Diabetic Retinopathy
6.5.4. Uveitis
6.5.5. Others
6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2023 - 2031
6.6.1. Institutional Sales
6.6.2. Retail Pharmacies
6.6.3. Mail Order Pharmacies
6.6.4. Retail Sales
6.7. Market Attractiveness Analysis
7. Europe Retinal Biologics Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
7.2.1. By Country
7.2.2. By Drug Class
7.2.3. By Indication
7.2.4. By Distribution Channel
7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Türkiye
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
7.4.1. VEGF-A Antagonists
7.4.2. TNF-a Inhibitors
7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
7.5.1. Macular Degeneration
7.5.2. Diabetic Macular Edema
7.5.3. Diabetic Retinopathy
7.5.4. Uveitis
7.5.5. Others
7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2023 - 2031
7.6.1. Institutional Sales
7.6.2. Retail Pharmacies
7.6.3. Mail Order Pharmacies
7.6.4. Retail Sales
7.7. Market Attractiveness Analysis
8. East Asia Retinal Biologics Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
8.2.1. By Country
8.2.2. By Drug Class
8.2.3. By Indication
8.2.4. By Distribution Channel
8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
8.4.1. VEGF-A Antagonists
8.4.2. TNF-a Inhibitors
8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
8.5.1. Macular Degeneration
8.5.2. Diabetic Macular Edema
8.5.3. Diabetic Retinopathy
8.5.4. Uveitis
8.5.5. Others
8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2023 - 2031
8.6.1. Institutional Sales
8.6.2. Retail Pharmacies
8.6.3. Mail Order Pharmacies
8.6.4. Retail Sales
8.7. Market Attractiveness Analysis
9. South Asia & Oceania Retinal Biologics Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
9.2.1. By Country
9.2.2. By Drug Class
9.2.3. By Indication
9.2.4. By Distribution Channel
9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
9.4.1. VEGF-A Antagonists
9.4.2. TNF-a Inhibitors
9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
9.5.1. Macular Degeneration
9.5.2. Diabetic Macular Edema
9.5.3. Diabetic Retinopathy
9.5.4. Uveitis
9.5.5. Others
9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2023 - 2031
9.6.1. Institutional Sales
9.6.2. Retail Pharmacies
9.6.3. Mail Order Pharmacies
9.6.4. Retail Sales
9.7. Market Attractiveness Analysis
10. Latin America Retinal Biologics Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
10.2.1. By Country
10.2.2. By Drug Class
10.2.3. By Indication
10.2.4. By Distribution Channel
10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
10.4.1. VEGF-A Antagonists
10.4.2. TNF-a Inhibitors
10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
10.5.1. Macular Degeneration
10.5.2. Diabetic Macular Edema
10.5.3. Diabetic Retinopathy
10.5.4. Uveitis
10.5.5. Others
10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2023 - 2031
10.6.1. Institutional Sales
10.6.2. Retail Pharmacies
10.6.3. Mail Order Pharmacies
10.6.4. Retail Sales
10.7. Market Attractiveness Analysis
11. Middle East & Africa Retinal Biologics Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
11.2.1. By Country
11.2.2. By Drug Class
11.2.3. By Indication
11.2.4. By Distribution Channel
11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
11.4.1. VEGF-A Antagonists
11.4.2. TNF-a Inhibitors
11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
11.5.1. Macular Degeneration
11.5.2. Diabetic Macular Edema
11.5.3. Diabetic Retinopathy
11.5.4. Uveitis
11.5.5. Others
11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2023 - 2031
11.6.1. Institutional Sales
11.6.2. Retail Pharmacies
11.6.3. Mail Order Pharmacies
11.6.4. Retail Sales
11.7. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2023
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Spark Therapeutics, Inc.
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. F. Hoffmann-La Roche Ltd.
12.3.2.1.Overview
12.3.2.2. Segments and Products
12.3.2.3. Key Financials
12.3.2.4. Market Developments
12.3.2.5. Market Strategy
12.3.3. Regeneron Pharmaceuticals, Inc.
12.3.3.1. Overview
12.3.3.2. Segments and Products
12.3.3.3. Key Financials
12.3.3.4. Market Developments
12.3.3.5. Market Strategy
12.3.4. AbbVie Inc.
12.3.4.1. Overview
12.3.4.2. Segments and Products
12.3.4.3. Key Financials
12.3.4.4. Market Developments
12.3.4.5. Market Strategy
12.3.5. Amgen Inc.
12.3.5.1. Overview
12.3.5.2. Segments and Products
12.3.5.3. Key Financials
12.3.5.4. Market Developments
12.3.5.5. Market Strategy
12.3.6. Novartis Pharma AG
12.3.6.1. Overview
12.3.6.2. Segments and Products
12.3.6.3. Key Financials
12.3.6.4. Market Developments
12.3.6.5. Market Strategy
12.3.7. MeiraGTx Limited
12.3.7.1. Overview
12.3.7.2. Segments and Products
12.3.7.3. Key Financials
12.3.7.4. Market Developments
12.3.7.5. Market Strategy
12.3.8. Oxurion NV
12.3.8.1. Overview
12.3.8.2. Segments and Products
12.3.8.3. Key Financials
12.3.8.4. Market Developments
12.3.8.5. Market Strategy
12.3.9. Santen Pharmaceutical Co., Ltd.
12.3.9.1. Overview
12.3.9.2. Segments and Products
12.3.9.3. Key Financials
12.3.9.4. Market Developments
12.3.9.5. Market Strategy
12.3.10. Bayer AG
12.3.10.1. Overview
12.3.10.2. Segments and Products
12.3.10.3. Key Financials
12.3.10.4. Market Developments
12.3.10.5. Market Strategy
12.3.11. Bausch Health Companies Inc.
12.3.11.1. Overview
12.3.11.2. Segments and Products
12.3.11.3. Key Financials
12.3.11.4. Market Developments
12.3.11.5. Market Strategy
12.3.12. Merck & Co., Inc.
12.3.12.1. Overview
12.3.12.2. Segments and Products
12.3.12.3. Key Financials
12.3.12.4. Market Developments
12.3.12.5. Market Strategy
12.3.13. Adverum Biotechnologies
12.3.13.1. Overview
12.3.13.2. Segments and Products
12.3.13.3. Key Financials
12.3.13.4. Market Developments
12.3.13.5. Market Strategy
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
